Michelle Corso

Current Trials

• 2000033529: A pilot study to evaluate biomarkers and safety of dapagliflozin concomitant with neoadjuvant therapy for patient with HER2-negative early-stage breast cancer and hyperinsulinemia (previously HIC 2000031461) [Yale HIC]

  HIC ID2000033529RoleSub InvestigatorPrimary Completion Date12/31/2025

  Recruiting Participants

  Breast Cancer

• The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

  HIC ID2000030282RoleSub InvestigatorPrimary Completion Date01/01/2028

  Recruiting Participants

  Breast Cancer

• A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer

  HIC ID2000029678RoleSub InvestigatorPrimary Completion Date12/15/2023

  Recruiting Participants

  Breast Cancer

• Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer

  HIC ID2000024170RoleSub InvestigatorPrimary Completion Date01/01/2035

  Recruiting Participants

  Breast Cancer

• I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

  HIC ID2000020575RoleSub InvestigatorPrimary Completion Date12/01/2030

  Recruiting Participants

  Breast Cancer